Form 483

ROVI Pharma Industrial Services S.A. Form 483, 2022-06-20

FDA issued a Form 483 to ROVI Pharma Industrial Services S.A. on 2022-06-20 with 4 public-safe observations.

483· Form 483 issuedHuman Drugs4 observations

ROVI Pharma Industrial Services S.A. · San Sebastian De Los Reyes, Spain · Issued June 20, 2022

Overview

  • 4 public-safe observations are available for this inspection.
  • 4 structured CFR citations are represented.
  • 1 investigator is tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

20 Jun 2022
21 CFR 211.113(b)

Procedures for sterile drug products

Cited by Arsen Karapetyan

20 Jun 2022
21 CFR 211.192

No written record of investigation

Cited by Arsen Karapetyan

20 Jun 2022
21 CFR 211.22(d)

Procedures not in writing, fully followed

Cited by Arsen Karapetyan

20 Jun 2022
21 CFR 211.63

Equipment Design, Size and Location

Cited by Arsen Karapetyan

Inspected site

RPROVI Pharma Industrial Services S.A.San Sebastian De Los Reyes, Spain

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 211.113(b)Cited across public-safe Form 483 observations1x
21 CFR 211.192Cited across public-safe Form 483 observations1x
21 CFR 211.22(d)Cited across public-safe Form 483 observations1x
21 CFR 211.63Cited across public-safe Form 483 observations1x

Source document

PDF
PDF available

Form 483 source document

The source document is available to authorized Atlas users.

Full 483 report

Get the verbatim text of all 4 observations

The source PDF, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere